Compare ARK Next Generation Internet ETF (ARKW) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Next Generation Internet ETF vs Biogen Inc — how do they compare? ARK Next Generation Internet ETF trades at $150.74, while Biogen Inc trades at $204.1 (market cap $30.13B). The key difference: Biogen Inc is trading nearer its 52-week high, ARK Next Generation Internet ETF nearer its low. Which is the better fit depends on your goals.
| ARKW | BIIB | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $182.20 | $216.63 |
52-Week Low | $114.45 | $128.93 |
Market Cap | — | $30.13B |
Enterprise Value | — | $37.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKW trades at $151.13, up 1.04% with strong technical momentum as moving averages signal bullish alignment. The ETF faces near-term headwinds from elevated AI infrastructure spending but maintains long-term growth positioning in next-generation internet technologies. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX confirms strong trend strength.
The ETF's outlook balances near-term capital expenditure pressures against long-term AI and technology exposure. Key risks include market skepticism toward growth stocks and concentration in volatile tech holdings. Analyst sentiment remains cautious with a Hold rating due to current market conditions despite the fund's innovative portfolio positioning.
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Next Generation Internet ETF
ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
